# Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

> **NCT02392676** · PHASE3 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Platinum Sensitive Relapsed Ovarian Cancer

## Interventions

- **DRUG:** OLAPARIB
- **DRUG:** PLACEBO

## Key facts

- **NCT ID:** NCT02392676
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-07
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is unlikely to be feasible given the evolving ovarian cancer landscape and alternative studies have the potential to meet future clinical demand.
- **Last updated:** 2016-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02392676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02392676, "Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02392676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*